RxDoctor Payments Data

Sheila Tano, MD

Psychiatry · Columbus, OHNPI 1306143722

Payments from drug & device makers

$692in general payments, 2019–2025

Across 44 payments — averaging $15.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$121
  • Lundbeck LLC$114
  • Otsuka America Pharmaceutical, Inc.$110
  • Neurocrine Biosciences, Inc.$82
  • Bausch Health US, LLC$73
  • AbbVie$62
  • plus $130 from 4 others

What the payments were for

  • Food & beverage$66396%
  • Education$304%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$692 in reported general payments places this provider in the 65th percentile of 1,119 psychiatry providers in Ohio.

See all psychiatry providers in Ohio

Medicare billing

Part B allowed, 2024
$14,167
Medicare patients
29
Services billed
144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl30$41,607
TrintellixVortioxetine Hydrobromide12$5,597
Aripiprazole37$5,476
Quetiapine Fumarate ErQuetiapine Fumarate63$2,185
Bupropion XlBupropion Hcl91$2,059
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine32$1,249
Duloxetine Hcl38$1,193
Paliperidone ErPaliperidone11$1,040
Buspirone Hcl95$924
Quetiapine Fumarate90$904
Mirtazapine56$839
Fluoxetine Hcl56$837
Fluvoxamine Maleate29$738
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine11$664
Olanzapine18$656

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$62$41,60730 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$35$5,59712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,119 psychiatry providers in Ohio.

Other psychiatry in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →